Ab­b­Vie’s PARP in­hibitor floun­ders in PhII as ri­vals surge ahead in late-stage dri­ve

Ab­b­Vie’s PARP in­hibitor veli­parib failed two key end­points in a Phase II study of metasta­t­ic breast can­cer with BR­CA1 or BR­CA2 mu­ta­tions.

In­ves­ti­ga­tors, in­clud­ing Heather Han from Mof­fitt, turned up at the San An­to­nio Breast Can­cer Sym­po­sium to re­port that the pro­gres­sion-free sur­vival rate of veli­parib com­bined with car­bo­platin and pa­cli­tax­el chemother­a­py was 14.1 months, an im­prove­ment but not a sta­tis­ti­cal­ly sig­nif­i­cant ad­vance when you com­pared the 12.3-month PFS rate in the group that sub­sti­tut­ed a place­bo for veli­parib. The over­all sur­vival rate — 28.3 months ver­sus 25.9 months — al­so failed to suf­fi­cient­ly di­verge.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER